BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) posted its quarterly earnings data on Wednesday. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:Get BioCryst Pharmaceuticals alerts:ORLADEYO revenue rose 10% year over year to $158.2 million on a comparable basis, with continued new-prescriber additions, stable demand and an improved paid rate of 84%. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.22. Recommended StoriesReceive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.